Absci Corporation stocks have been trading up by 10.86 percent amid bullish sentiment on its latest AI drug-discovery advances.
What Traders Need To Know
- BTIG initiated coverage on Absci with a Buy rating and a $9 price target, highlighting its AI drug creation platform and projecting $2.2B peak sales for ABS-201 in hair loss and endometriosis.
- JonesResearch raised its price target to $11 from $9 and reiterated a Buy rating, pointing to ABS-201’s safety and confirming androgenetic alopecia data timing in 2H 2026.
- Morgan Stanley trimmed its target to $4.10 from $4.20 with an Equal Weight rating, while the Street’s average rating remains Buy with a mean target around $8.76–$8.79.
- A 276,200-share stock option grant at $4.92 to a new employee under the 2023 Inducement Plan reinforces focus on AI-designed lead asset ABS-201 for hair regrowth and endometriosis.
Weekly Update May 25 – May 29, 2026: On Sunday, May 31, 2026 Absci Corporation stock [NASDAQ: ABSI] is trending up by 10.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Absci (ABSI) is an early‑stage AI drug creation platform with negligible revenue ($0.2M in Q1 2026; $2.8M TTM) and extreme negative margins (EBIT margin ~‑6,400%) reflecting a pure R&D story rather than an operating business. Cash burn is heavy (Q1 operating cash flow ‑$26.3M; FCF ‑$26.3M) but the balance sheet is solid for now: $125.7M cash and investments, minimal debt (D/E ~0.03), and strong liquidity (current ratio 6.6). Returns on capital are deeply negative, but that is typical for pre‑commercial biotech.
Technically, ABSI has transitioned from consolidation to a short‑term breakout. The weekly range from roughly $5.2 to $6.99 shows accelerating upside, with successive higher closes and a strong move from $5.16 to $6.74, implying a clear bullish trend supported by expanding volume on up‑days. Near term, $6.00 is the first meaningful support and a logical trading pivot; sustained closes above $7.00 open room toward the high‑single‑digits, while a breakdown below $5.20 would invalidate the current momentum.
More Breaking News
- CareDx CDNA Rips Higher After Big Earnings Beat And Guidance Hike
- REGN Stock Jumps As Bullish Data And Targets Pile Up
- BMNR Stock Pulls Back As Traders Gauge Risk
- Global Payments Stock Climbs As Analysts Bet On Worldpay Upside
Near‑term catalysts skew favorable: positive Q1 commentary on ABS‑201 safety, BTIG’s Buy with a $9 target and $2.2B peak‑sales view, and JonesResearch’s target hike to $11 all reinforce the AI‑biologics leadership narrative, even as Morgan Stanley remains cautious at $4.10. Versus broader Healthcare and Biotech benchmarks, ABSI is much earlier‑stage but has materially higher upside optionality if ABS‑201 validates. I assign a decisive positive bias with a 12‑18 month fair‑value band of $8–$10, with support at $6 and resistance near $9.
Quick Financial Overview
Absci Corporation (ABSI) is trading in an active upswing, with weekly closes moving from roughly the mid-$5 area to the high-$6 area in late 2026/05. The stock jumped from about $5.16 to $6.74 over the latest weekly stretch, showing strong momentum. Intraday, a single wide 5-minute bar printed a move from just under $6 to a high in the low-$7s before settling around $6.75, signaling aggressive buying and volatility.
On the fundamental side, Absci Corporation remains an early-stage, high-burn biotech tightly tied to its AI platform and ABS-201. Quarterly revenue was only about $0.22M, while total expenses ran above $31M, driving a net loss near $29.6M and heavily negative margins. Price-to-sales near 573 and price-to-book above 6 show traders are paying up for future potential, not current earnings.
The balance sheet, however, gives ABSI runway. Cash, cash equivalents, and short-term investments are about $125.7M, with working capital around $111.9M and very low debt, as shown by a total debt-to-equity ratio near 0.03 and a current ratio around 6.6. Operating cash flow was roughly -$26.3M for the quarter, offset partly by equity issuance, so dilution is a live factor for traders. The core trade here is whether the AI-designed ABS-201 story and bullish analyst targets justify these rich multiples and ongoing cash burn.
Conclusion
Absci Corporation sits in a classic high-risk, high-reward biotech zone where narrative and catalysts drive the tape more than current earnings. The recent surge from the $5s into the high-$6s came alongside upbeat analyst coverage, with BTIG launching at Buy with a $9 target and JonesResearch lifting its target to $11. These calls lean heavily on the ABS-201 opportunity in androgenetic alopecia and endometriosis, including a bold $2.2B peak sales view and GLP-1-like framing for hair loss.
At the same time, Morgan Stanley’s trimmed $4.10 target and Equal Weight stance remind traders that valuation and execution risk are real. Financials confirm that ABSI is burning cash fast, with deep negative margins and heavy R&D spend, even if the balance sheet currently looks strong with over $100M in liquidity and modest debt. For short-term trading, the key is to respect both the upside momentum and the downside air pocket.
For traders tracking ABSI, the main levers are continued analyst commentary, any updates around ABS-201 safety or timelines, and how the stock behaves around new highs and pullbacks. Tight risk management is non-negotiable in a name priced for future success. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” That’s especially true in speculative biotech, where journaling how you navigate breakouts, fades, and headline risk can sharpen your edge over time. As I tell my students, “The market will pay you big for being early to the right story, but only if you control your downside every single trade.”
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.